New publication: Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers

A publication about formulation and dose selection for further clinical development of a sustained release formulation in the treatment of cryptococcal meningoencephalitis. 

This research contributes to combating infectious diseases, and by innovative formulations and optimization of dosing, aim to enhance treatment accessibility and efficacy, ultimately improving lives of those affected by cryptococcal meningoencephalitis.